Recent advances in SLN and NLC-based lipid nanoparticles for cosmetic, dermal, and transdermal drug delivery: A comprehensive review.
- 1Department of Pharmaceutics, (Affiliated to Shivaji University, Kolhapur) Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangli, Maharashtra, India.
Abstract
Recent advances in nanotechnology have positioned solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as promising platforms for dermal and transdermal drug delivery. This review critically highlights emerging breakthroughs that go beyond the conventional advantages of lipid nanoparticles. SLNs, composed of physiologically compatible solid lipids, provide improved drug stability and controlled release; however, their clinical utility is often constrained by limited drug loading, drug expulsion during storage, and highly ordered crystalline structures. To overcome these drawbacks, second-generation NLCs incorporate both solid and liquid lipids, creating an imperfect lipid matrix that significantly enhances loading capacity, minimizes drug leakage, and enables tunable release kinetics. Recent formulation innovations including precision high-pressure homogenization, microfluidic-assisted production, and optimized hot/cold homogenization approaches have enabled tighter particle size control, improved batch reproducibility, and better long-term stability. In parallel, surface engineering strategies such as ligand functionalization, polymer coating, and incorporation of natural bioactives have demonstrated enhanced skin targeting, deeper stratum corneum penetration, and prolonged dermal retention. Notably, recent preclinical and translational studies report improved therapeutic outcomes in acne, psoriasis, fungal infections, inflammatory disorders, wound healing, hyperpigmentation, and melanoma-related skin conditions when compared with conventional topical systems. Despite these advances, important translational gaps remain, including large-scale manufacturing challenges, regulatory uncertainties, and limited clinical validation. By integrating recent technological breakthroughs with application-focused evidence, this review provides a forward-looking perspective on the evolving role of SLNs and NLCs as next-generation lipid nanocarriers for dermatological therapy and advanced skin care.
Related
- Selenium Nanoparticles in Atherosclerosis and Non-Alcoholic Fatty Liver Disease: A Comprehensive Review of Therapeutic Mechanisms, Targeted Delivery, and Translational Prospects
- Human Skin Permeability Prediction by Machine Learning for Transdermal Drug Delivery
- Methodical design, development, and evaluation of transferosomal transdermal films for enhanced delivery of lornoxicam and thiocolchicoside
- Revolutionizing transdermal drug delivery evaluation: the evolution from traditional models to skin organoids and the integration of artificial intelligence
- Multifunctional gelatin/PVA hydrogels chemically crosslinked with grape pomace extract for controlled transdermal delivery of polyphenolic compounds
BibTeX
@article{kavathekar2026recent,
title = {{Recent advances in SLN and NLC-based lipid nanoparticles for cosmetic, dermal, and transdermal drug delivery: A comprehensive review.}},
author = {Prajakta Kirankumar Kavathekar and Pravin K Pawar},
journal = {BioImpacts : BI},
year = {2026},
month = aug,
doi = {10.34172/bi.33400},
url = {https://europepmc.org/article/MED/42898394},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Recent advances in SLN and NLC-based lipid nanoparticles for cosmetic, dermal, and transdermal drug delivery: A comprehensive review.
AU - Prajakta Kirankumar Kavathekar
AU - Pravin K Pawar
PY - 2026
DA - 2026/08/09
JO - BioImpacts : BI
DO - 10.34172/bi.33400
UR - https://europepmc.org/article/MED/42898394
AB - Recent advances in nanotechnology have positioned solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as promising platforms for dermal and transdermal drug delivery. This review critically highlights emerging breakthroughs that go beyond the conventional advantages of lipid nanoparticles. SLNs, composed of physiologically compatible solid lipids, provide improved drug stability and controlled release; however, their clinical utility is often constrained by limited drug loading, drug expulsion during storage, and highly ordered crystalline structures. To overcome these drawbacks, second-generation NLCs incorporate both solid and liquid lipids, creating an imperfect lipid matrix that significantly enhances loading capacity, minimizes drug leakage, and enables tunable release kinetics. Recent formulation innovations including precision high-pressure homogenization, microfluidic-assisted production, and optimized hot/cold homogenization approaches have enabled tighter particle size control, improved batch reproducibility, and better long-term stability. In parallel, surface engineering strategies such as ligand functionalization, polymer coating, and incorporation of natural bioactives have demonstrated enhanced skin targeting, deeper stratum corneum penetration, and prolonged dermal retention. Notably, recent preclinical and translational studies report improved therapeutic outcomes in acne, psoriasis, fungal infections, inflammatory disorders, wound healing, hyperpigmentation, and melanoma-related skin conditions when compared with conventional topical systems. Despite these advances, important translational gaps remain, including large-scale manufacturing challenges, regulatory uncertainties, and limited clinical validation. By integrating recent technological breakthroughs with application-focused evidence, this review provides a forward-looking perspective on the evolving role of SLNs and NLCs as next-generation lipid nanocarriers for dermatological therapy and advanced skin care.
SN - 2228-5652
SN - 2228-5660
ER -